Fundsmith LLP Sells 1,307 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fundsmith LLP decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 2,662,855 shares of the company’s stock after selling 1,307 shares during the period. IDEXX Laboratories accounts for about 4.7% of Fundsmith LLP’s holdings, making the stock its 10th largest position. Fundsmith LLP’s holdings in IDEXX Laboratories were worth $1,100,931,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IDXX. Sax Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock worth $590,000 after purchasing an additional 617 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of IDEXX Laboratories by 11.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock worth $3,199,000 after buying an additional 800 shares during the period. Paragon Capital Management Inc. boosted its holdings in shares of IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock valued at $1,579,000 after acquiring an additional 782 shares in the last quarter. Manitou Investment Management Ltd. raised its holdings in IDEXX Laboratories by 491.0% during the fourth quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company’s stock worth $21,582,000 after purchasing an additional 43,369 shares in the last quarter. Finally, Fiera Capital Corp lifted its position in IDEXX Laboratories by 12.3% in the fourth quarter. Fiera Capital Corp now owns 141,198 shares of the company’s stock worth $58,377,000 after purchasing an additional 15,463 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research report on Monday, April 14th. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 12th. Finally, Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $524.75.

IDEXX Laboratories Trading Up 0.7 %

IDXX stock opened at $489.98 on Friday. The business has a fifty day moving average of $422.31 and a 200-day moving average of $429.15. The company has a market cap of $39.71 billion, a P/E ratio of 45.92, a PEG ratio of 3.41 and a beta of 1.52. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. During the same quarter last year, the firm earned $2.71 EPS. IDEXX Laboratories’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.